123 123 123 123 123 123
         
 
 

Financials

3-year Snapshot

Consolidated Income Statement Data

 

Thousands of Euro (€)
2009
2008
2007
Revenues
2548
3024
2641
Cost of goods & services sold
-179
-243
-450
Gross profit
2369
2781
2191
Research and development expenses
-13089
-10999
-10699
Selling, general and administrative expenses
-4011
-3107
-2463
Other operating income
0
0
9
Other operating expenses
0
-1
-9
Operating Profit (EBIT)
-14731
-11326
-10971
Financial result
430
1134
996
Profit / (Loss) before taxes
-14301
-10192
-9975
Income taxes
0
0
0
Net profit / (Loss)
-14301
-10192
-9975

 

Consolidated Balance Sheet Data

 

ASSETS  
 
Thousands of Euro (€)
2009
2008
2007
Total non-current assets
1976
4660
3427
Total current assets
22776
34392
36477
Of which cash and cash equivalents
18032
30601
33103
Total assets
24752
39052
39904
 
LIABILITIES AND SHAREHOLDERS’ EQUITY
Total equity
18800
32643
34122
Non-current liabilities
557
1252
1344
Current liabilities
5395
5157
4438
Total liabilities and shareholders’ equity
24752
39052
39904

 

Consolidated Cash Flow Statement

 

Thousands of Euro (€)
2009
2008
2007
Net cash provided by / (used in) operating activities
-12798
-9313
-11301
Net cash provided by / (used in) investing activities
118
-1619
275
Net cash provided by / (used in) financing activities
109
8473
11274
Net change in cash and cash equivalents
-12571
-2459
248
Cash and cash equivalents at end of period
18032
30601
33103

 

Financial Reports

2010 Half Year Results:

2009 Annual Report :

2009 Full Year Results:

2009 Half Year Results:

2008 Annual Report :

2008 Full Year Results:

2008 Half Year Results:

2007 Annual Report:

2007 Full Year Results:

2007 Half Year Results:


2006 Annual Report:

2006 Full Year Results:

2006 Statutory Financial Statements (Fench Only):

2006 Half Year Results:

Please click here to download the Listing prospectus (December 2008).

Accounting Standards

The statutory financial statements are prepared respectively in accordance with generally accepted accounting principles in Belgium or Belgian GAAP.
The consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS).

 

 
Contact

Investors Inquiries
Mr. Philip Devine
Tour 5 GIGA niveau +3
Av. de l’Hôpital 11
4000 Liege -  BELGIUM
T: +32 (0)4 364 20 70
F: +32 (0)4 364 20 71
E: ir@oncomethylome.com

Stay Informed

Sign up for OncoMethylome Sciences' financial news subscription service.

register now